Errata

Abstract

BJU InternationalVolume 94, Issue 4 p. 700-700 Free Access Errata First published: 25 August 2004 https://doi.org/10.1111/j.1464-410X.2004.05124.xAboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat In [1], the following errors were published on pages 1179 and 1181. Figure 3 legend Fig. 3. Overall survival data as HRs for combination therapy compared with castration alone from published meta-analyses. Figure reproduced with permission from [4]. Derived from information in [3]; †Relative risks using data from [3]; CPA, cyproterone acetate; FLUT, flutamide; NILUT, nilutamide; NSAA, nonsteroidal antiandrogen; NSAA(LH), relative risks (log HR) from P-values; NSAA(PH), relative risks (proportional hazards) from discrete proportional hazards model. The text was incorrect and should have read: Figure 3 and legend Fig. 3. Overall survival data as HRs for combination therapy compared with castration alone from published meta-analyses. Figure reproduced with permission from [14]. Derived from information in [3]; †Relative risks using data from [3]; CPA, cyproterone acetate; FLUT, flutamide; NILUT, nilutamide; NSAA, nonsteroidal antiandrogen; NSAA(LH), relative risks (log HR) from P-values; NSAA(PH), relative risks (proportional hazards) from discrete proportional hazards model. Figure 1Open in figure viewerPowerPoint The references 15–18 which are alluded to in this figure were omitted from the published paper; they are given below. 15 Caubet J-F, Tosteson TD, Dong EW et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997; 49: 71– 8 CrossrefCASPubMedWeb of Science®Google Scholar 16 Klotz LH, Newman T and the Ontario Practice Guidelines Initiative. Total androgen blockade for metastatic prostate cancer: history and analysis of the PCTCG overview. Can J Urol 1996; 3 (Suppl 1): 102– 5 Google Scholar 17 Debruyne FMJ, De Géry A, Hucher M, Godfroid N. Maximum androgen blockade with nilutamide combined with orchidectomy in advanced prostate cancer: an updated metaanalysis of 7 randomised, placebo-controlled trials (1191 patients). Eur Urol 1996; 30 (Suppl 2): 264 Google Scholar 18 Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis on nine published randomised controlled trials and 4128 patients using flutamide. Prostate Cancer PD 1999; 2: 4– 8 CrossrefCASPubMedWeb of Science®Google Scholar We apologize for these errors. REFERENCE 1 Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 2004; 93: 1177– 82 Wiley Online LibraryCASPubMedWeb of Science®Google Scholar Volume94, Issue4September 2004Pages 700-700 FiguresReferencesRelatedInformation